Wall Street was quick to cheer the Trump
blueprint, unveiled on May 11. Right after it was announced, prices on pharmaceutical stocks soared. And even though Trump had promised to go after pharmacy benefit managers—middlemen between drug-maker and insurers who take a cut of the industry’s profits—his policy prescriptions spared them, and their stock prices
soared too.
